Related Experiment Video

Updated: May 22, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics

L Y Dimberg1, C K Anderson, R Camidge

  • 1Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, CO, USA.

Oncogene
|May 15, 2012
PubMed

Insights

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) therapy shows promise for cancer treatment but faces resistance. Identifying biomarkers to predict patient response is crucial for maximizing TRAIL

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its death receptor (DR) agonists offer targeted cancer cell death with minimal harm to normal tissues.
  • Several novel TRAIL receptor-targeting drugs are in clinical development, indicating significant therapeutic interest.
  • TRAIL resistance presents a major challenge, limiting the clinical efficacy of these promising agents.

Purpose of the Study:

  • To review mechanisms of TRAIL resistance in cancer therapy.
  • To explore strategies for predicting and overcoming TRAIL resistance.
  • To provide an overview of TRAIL-based clinical trials and identify patient selection criteria.

Main Methods:

  • Literature review of TRAIL resistance mechanisms.
  • Analysis of clinical trial data for TRAIL-based therapies.
  • Discussion of predictive biomarkers for TRAIL sensitivity.

Main Results:

  • TRAIL therapy demonstrates modest overall efficacy but elicits strong responses in a subset of patients.
  • Various mechanisms contribute to TRAIL resistance, impacting treatment outcomes.
  • Clinical trials highlight the need for patient stratification to improve TRAIL therapy success.

Conclusions:

  • Targeting TRAIL DRs holds significant potential for cancer treatment, contingent on effective patient selection.
  • Identifying biomarkers for TRAIL sensitivity is essential to unlock the full therapeutic benefit.
  • Overcoming TRAIL resistance through predictive and therapeutic strategies is key to advancing TRAIL-based oncology.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...